白芍总苷治疗强直性脊柱炎临床疗效及对血清炎性因子水平的影响
|
摘要
目的研究白芍总苷胶囊联合柳氮磺吡啶治疗强直性脊柱炎(AS)的临床疗效及对血清炎性因子水平的影响。方法回顾性分析2015年2月—2017年6月收治的AS 92例的临床资料,根据不同治疗方式分为对照组和观察组,每组46例,对照组采取柳氮磺吡啶肠溶片治疗,观察组在对照组基础上联合白芍总苷胶囊治疗,2组均治疗2个月。对比2组症状评分及临床疗效、血清白介素(IL)-1β、IL-17、C反应蛋白(CRP)水平,治疗前后病情活动指标(BASDAI)、功能指数(BASFI)评分和不良反应情况。结果治疗后,2组下腰背疼痛、外周关节疼痛、外周关节肿胀评分及血清CRP、IL-1β、IL-17水平和BASDAI、BASFI评分均低于治疗前,且观察组低于对照组(P <0. 05,P <0. 01);观察组总有效率高于对照组(P <0. 05); 2组不良反应发生率比较差异无统计学意义(P> 0. 05)。结论白芍总苷胶囊联合柳氮磺吡啶治疗AS临床疗效好,可明显改善患者的症状,降低机体炎性因子水平,安全可靠。
Objective To study clinical effectiveness of Baishaozonggan Capsule combined with Sulfasalazine in treatment of patients with ankylosing spondylitis( AS) and its effects on serum inflammatory factors levels. Methods Clinical data of 92 patients with ankylosing spondylitis admitted during February 2015 and June 2017 was retrospectively analyzed,and the patients were divided into control group and observation group( n = 46 for each group) according to different treatment methods. Control group was treated with Sulfasalazine Enteric-coated Tablets,while observation group was added with Baishaozonggan Capsule on the basis of treatment for control group,and two groups were all treated for two months. Symptom scores,clinical effectiveness,serum interleukin-1β( IL-1β),interleukin-l7( IL-17),serum C reaction protein( CRP),the Bath ankylosing spondylitis disease activity index( BASDAI) score,Bath ankylosing spondylitis functional index( BASFI) score and incidence rate of adverse reactions before and after treatment were compared between two groups. Results After treatment,scores of lower lumbar and back pain,peripheral joint pain and peripheral joint swelling,serum CRP,IL-1β and IL-17 levels,BASDAI and BASFI values were significantly decreased compared with those before treatment in two groups,and the values in observation group were significantly lower than those in control group( P < 0. 05,P < 0. 01). The total effective rate in observation group was significantly higher than that in control group( P < 0. 05). There was no significant difference in incidence rate of adverse reactions between two groups( P <0. 05). Conclusion Baishaozonggan Capsule combined with Sulfasalazine in treatment of patients with ankylosing spondylitis may achieve good clinical effectiveness,significantly improve patients' symptoms and reduce secretion of inflammatory factors.
Objective To study clinical effectiveness of Baishaozonggan Capsule combined with Sulfasalazine in treatment of patients with ankylosing spondylitis( AS) and its effects on serum inflammatory factors levels. Methods Clinical data of 92 patients with ankylosing spondylitis admitted during February 2015 and June 2017 was retrospectively analyzed,and the patients were divided into control group and observation group( n = 46 for each group) according to different treatment methods. Control group was treated with Sulfasalazine Enteric-coated Tablets,while observation group was added with Baishaozonggan Capsule on the basis of treatment for control group,and two groups were all treated for two months. Symptom scores,clinical effectiveness,serum interleukin-1β( IL-1β),interleukin-l7( IL-17),serum C reaction protein( CRP),the Bath ankylosing spondylitis disease activity index( BASDAI) score,Bath ankylosing spondylitis functional index( BASFI) score and incidence rate of adverse reactions before and after treatment were compared between two groups. Results After treatment,scores of lower lumbar and back pain,peripheral joint pain and peripheral joint swelling,serum CRP,IL-1β and IL-17 levels,BASDAI and BASFI values were significantly decreased compared with those before treatment in two groups,and the values in observation group were significantly lower than those in control group( P < 0. 05,P < 0. 01). The total effective rate in observation group was significantly higher than that in control group( P < 0. 05). There was no significant difference in incidence rate of adverse reactions between two groups( P <0. 05). Conclusion Baishaozonggan Capsule combined with Sulfasalazine in treatment of patients with ankylosing spondylitis may achieve good clinical effectiveness,significantly improve patients' symptoms and reduce secretion of inflammatory factors.
引文
[1]王旭光,杨大男.自拟益肾通督汤结合柳氮磺胺吡啶与美洛昔康治疗强直性脊柱炎[J].国际中医中药杂志,2016,38(1):41-44.
[2]杨润薇.益赛普、柳氮磺吡啶联合功能锻炼治疗强直性脊柱炎效果系统评价[J].贵州医药,2016,40(1):48-49.
[3]孟利花.沙利度胺联合柳氮磺吡啶对强直性脊柱炎的临床疗效和安全性评估[J].山西医药杂志,2016,45(5):596-598.
[4]蔡波,成百朵,强建红.壮腰健肾丸联合柳氮磺吡啶治疗强直性脊柱炎的临床研究[J].现代药物与临床,2016,31(9):1399-1402.
[5]方利,刘健,朱福兵.新风胶囊对强直性脊柱炎活动期患者血栓形成因子及炎症细胞因子的影响[J].中国中西医结合杂志,2016,36(10):1202-1207.
[6]韩爽,匡洪宇.强直性脊柱炎误诊为骨性关节炎一例并文献复习[J].临床误诊误治,2018,34(1):13-14.
[7]高巧霞.督灸联合补肾祛寒化湿中药治疗强直性脊柱炎肾虚督寒证疗效及对ESR、炎性细胞因子的影响[J].现代中西医结合杂志,2017,26(10):1103-1106.
[8]孙学明,刘磊,曹君君,等.沙利度胺联合柳氮磺吡啶治疗强直性脊柱炎的疗效观察[J].药物评价研究,2017,41(10):1477-1480.
[9]姜益常,李远峰,宋寒冰,等.补肾强督祛湿法治疗肾虚督寒型强直性脊柱炎的临床疗效评价[J].中医药学报,2017,45(4):83-86.
[10]陈倩倩,刘刚.补阳还五汤联合柳氮磺吡啶治疗强直性脊柱炎疗效观察[J].现代中西医结合杂志,2016,25(34):3810-3812.
[11]窦强,刘佳春,高杰,等.柳氮磺胺吡啶联合心理干预治疗强直性脊柱炎临床疗效及对患者心理的影响[J].中国骨与关节杂志,2017,6(4):297-300.
[12]辛昊洋,王澎澎,马玉琛.二活附子方治疗强直性脊柱炎的临床疗效及安全性评价[J].解放军医药杂志,2016,28(3):96-100.
[13]方利,刘健,朱福兵,等.新风胶囊对强直性脊柱炎活动期患者血液高凝状态影响及其机制探讨[J].世界中西医结合杂志,2016,11(7):949-955.
[14]黎旭军,何晖,黄健林,等.强直性脊柱炎早中期腰背痛的中医干预研究[J].辽宁中医杂志,2017,61(4):786-789.
[15]杨婧,孙红兵,帅世全,等. TWEAK及IL-17在强直性脊柱炎发病中的作用[J].西部医学,2016,28(11):1566-1569.
[16]陈倩倩.五藤汤加减对活动期强直性脊柱炎患者血栓形成因子的影响及作用机制初探[J].四川中医,2017,37(8):93-96.
[17]陈汉玉,兰培敏.扶阳强脊散结合离子导入治疗活动期肾虚瘀阻证强直性脊柱炎疗效及对各指标的影响[J].现代中西医结合杂志,2017,26(31):3428-3431.
[18] Tang P,Tang B,Wang Q,et al. Effect of hydroxypropyl-β-cyclodextrin on the bounding of salazosulfapyridine to human serum albumin[J]. Int J Biol Macromol,2016,92(3):105-115.
[19]符维广,李浩鹏.重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗强直性脊柱炎的临床效果[J].中国医药导报,2017,14(6):112-115.
[20]马伯俊,吴志君,林映欣.强直性脊柱炎患者采用中药汤剂联合针灸治疗临床疗效研究[J].河北中医药学报,2017,33(5):20-22.
[21]韩青,梁强,吴振彪,等.生物制剂联合甲氨蝶呤和柳氮磺胺吡啶治疗强直性脊柱炎伴髋关节炎的临床疗效[J].中华临床免疫和变态反应杂志,2017,12(4):233-235.
[22] Ma X F,Wang X D,Liu R R,et al. Efficacy research of salazosulfamide in ankylosing spondylitis and NAT1 gene polymorphism.[J]. Exp Ther Med,2017,14(4):2999-3003.
[23]王健,吉健华,王医林,等.沙利度胺与柳氮磺吡啶治疗强直性脊柱炎效果比较观察[J].人民军医,2016,69(1):45-47.
[24]徐萍,陶洪,袁良俊.中医辨证论治联合柳氮磺胺吡啶治疗强直性脊柱炎[J].成都医学院学报,2016,11(3):345-349.
[25]叶文芳,刘健,万磊,等.新风胶囊对强直性脊柱炎患者疗效及血清免疫球蛋白亚型、外周血淋巴细胞自噬的影响[J].中国中西医结合杂志,2016,36(3):310-316.
[26]田元生,唐迪,田晨辉,等.任督周天大艾灸联合柳氮磺胺吡啶治疗强直性脊柱炎临床观察[J].中国针灸,2016,36(10):1037-1040.
[27]吴海燕,华丽.沙利度胺联合柳氮磺胺吡啶治疗强直性脊柱炎[J].临床骨科杂志,2016,19(6):682-684.
[28]郑擎,徐鸣俊.重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白治疗强直性脊柱炎的临床研究[J].中国临床药理学杂志,2016,32(17):1561-1564.
[29]冯慧钧.中医针灸对强直性脊柱炎患者疼痛疗效及生活质量的影响[J].世界中医药,2017,13(1):573.
[30]王新刚,黄立,林强,等.蠲痹通络汤联合双氯芬酸钠肠溶缓释胶囊治疗强直性脊柱炎疗效观察[J].陕西中医,2017,38(10):1435-1436.
[31]刘强,熊小云.丹鹿通督片联合柳氮磺吡啶治疗强直性脊柱炎的临床研究[J].现代药物与临床,2017,32(3):472-476.
[32] Okada M,Fujii H,Suga Y,et al. Drug interaction between methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis[J]. J Pharm Health Care Sci,2017,3(1):7-9.
[33]赫军,诸葛天谕,李冬冬,等.独活寄生汤为主的中医综合疗法治疗强直性脊柱炎(脊痹寒湿犯腰证)的临床观察[J].中国中医骨伤科杂志,2017,26(2):19-23.
[34]王淑兰,陈宗林,周静,等.中药塌渍联合肿瘤坏死因子拮抗剂治疗活动性强直性脊柱炎的临床观察与护理[J].中国实用护理杂志,2016,32(14):1089-1093.
[2]杨润薇.益赛普、柳氮磺吡啶联合功能锻炼治疗强直性脊柱炎效果系统评价[J].贵州医药,2016,40(1):48-49.
[3]孟利花.沙利度胺联合柳氮磺吡啶对强直性脊柱炎的临床疗效和安全性评估[J].山西医药杂志,2016,45(5):596-598.
[4]蔡波,成百朵,强建红.壮腰健肾丸联合柳氮磺吡啶治疗强直性脊柱炎的临床研究[J].现代药物与临床,2016,31(9):1399-1402.
[5]方利,刘健,朱福兵.新风胶囊对强直性脊柱炎活动期患者血栓形成因子及炎症细胞因子的影响[J].中国中西医结合杂志,2016,36(10):1202-1207.
[6]韩爽,匡洪宇.强直性脊柱炎误诊为骨性关节炎一例并文献复习[J].临床误诊误治,2018,34(1):13-14.
[7]高巧霞.督灸联合补肾祛寒化湿中药治疗强直性脊柱炎肾虚督寒证疗效及对ESR、炎性细胞因子的影响[J].现代中西医结合杂志,2017,26(10):1103-1106.
[8]孙学明,刘磊,曹君君,等.沙利度胺联合柳氮磺吡啶治疗强直性脊柱炎的疗效观察[J].药物评价研究,2017,41(10):1477-1480.
[9]姜益常,李远峰,宋寒冰,等.补肾强督祛湿法治疗肾虚督寒型强直性脊柱炎的临床疗效评价[J].中医药学报,2017,45(4):83-86.
[10]陈倩倩,刘刚.补阳还五汤联合柳氮磺吡啶治疗强直性脊柱炎疗效观察[J].现代中西医结合杂志,2016,25(34):3810-3812.
[11]窦强,刘佳春,高杰,等.柳氮磺胺吡啶联合心理干预治疗强直性脊柱炎临床疗效及对患者心理的影响[J].中国骨与关节杂志,2017,6(4):297-300.
[12]辛昊洋,王澎澎,马玉琛.二活附子方治疗强直性脊柱炎的临床疗效及安全性评价[J].解放军医药杂志,2016,28(3):96-100.
[13]方利,刘健,朱福兵,等.新风胶囊对强直性脊柱炎活动期患者血液高凝状态影响及其机制探讨[J].世界中西医结合杂志,2016,11(7):949-955.
[14]黎旭军,何晖,黄健林,等.强直性脊柱炎早中期腰背痛的中医干预研究[J].辽宁中医杂志,2017,61(4):786-789.
[15]杨婧,孙红兵,帅世全,等. TWEAK及IL-17在强直性脊柱炎发病中的作用[J].西部医学,2016,28(11):1566-1569.
[16]陈倩倩.五藤汤加减对活动期强直性脊柱炎患者血栓形成因子的影响及作用机制初探[J].四川中医,2017,37(8):93-96.
[17]陈汉玉,兰培敏.扶阳强脊散结合离子导入治疗活动期肾虚瘀阻证强直性脊柱炎疗效及对各指标的影响[J].现代中西医结合杂志,2017,26(31):3428-3431.
[18] Tang P,Tang B,Wang Q,et al. Effect of hydroxypropyl-β-cyclodextrin on the bounding of salazosulfapyridine to human serum albumin[J]. Int J Biol Macromol,2016,92(3):105-115.
[19]符维广,李浩鹏.重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗强直性脊柱炎的临床效果[J].中国医药导报,2017,14(6):112-115.
[20]马伯俊,吴志君,林映欣.强直性脊柱炎患者采用中药汤剂联合针灸治疗临床疗效研究[J].河北中医药学报,2017,33(5):20-22.
[21]韩青,梁强,吴振彪,等.生物制剂联合甲氨蝶呤和柳氮磺胺吡啶治疗强直性脊柱炎伴髋关节炎的临床疗效[J].中华临床免疫和变态反应杂志,2017,12(4):233-235.
[22] Ma X F,Wang X D,Liu R R,et al. Efficacy research of salazosulfamide in ankylosing spondylitis and NAT1 gene polymorphism.[J]. Exp Ther Med,2017,14(4):2999-3003.
[23]王健,吉健华,王医林,等.沙利度胺与柳氮磺吡啶治疗强直性脊柱炎效果比较观察[J].人民军医,2016,69(1):45-47.
[24]徐萍,陶洪,袁良俊.中医辨证论治联合柳氮磺胺吡啶治疗强直性脊柱炎[J].成都医学院学报,2016,11(3):345-349.
[25]叶文芳,刘健,万磊,等.新风胶囊对强直性脊柱炎患者疗效及血清免疫球蛋白亚型、外周血淋巴细胞自噬的影响[J].中国中西医结合杂志,2016,36(3):310-316.
[26]田元生,唐迪,田晨辉,等.任督周天大艾灸联合柳氮磺胺吡啶治疗强直性脊柱炎临床观察[J].中国针灸,2016,36(10):1037-1040.
[27]吴海燕,华丽.沙利度胺联合柳氮磺胺吡啶治疗强直性脊柱炎[J].临床骨科杂志,2016,19(6):682-684.
[28]郑擎,徐鸣俊.重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白治疗强直性脊柱炎的临床研究[J].中国临床药理学杂志,2016,32(17):1561-1564.
[29]冯慧钧.中医针灸对强直性脊柱炎患者疼痛疗效及生活质量的影响[J].世界中医药,2017,13(1):573.
[30]王新刚,黄立,林强,等.蠲痹通络汤联合双氯芬酸钠肠溶缓释胶囊治疗强直性脊柱炎疗效观察[J].陕西中医,2017,38(10):1435-1436.
[31]刘强,熊小云.丹鹿通督片联合柳氮磺吡啶治疗强直性脊柱炎的临床研究[J].现代药物与临床,2017,32(3):472-476.
[32] Okada M,Fujii H,Suga Y,et al. Drug interaction between methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis[J]. J Pharm Health Care Sci,2017,3(1):7-9.
[33]赫军,诸葛天谕,李冬冬,等.独活寄生汤为主的中医综合疗法治疗强直性脊柱炎(脊痹寒湿犯腰证)的临床观察[J].中国中医骨伤科杂志,2017,26(2):19-23.
[34]王淑兰,陈宗林,周静,等.中药塌渍联合肿瘤坏死因子拮抗剂治疗活动性强直性脊柱炎的临床观察与护理[J].中国实用护理杂志,2016,32(14):1089-1093.